Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Iovance Biotherapeutics Inc’s stock clocked out at $3.08, up 0.65% from its previous closing price of $3.06. In other words, the price has increased by $0.65 from its previous closing price. On the day, 9.64 million shares were traded. IOVA stock price reached its highest trading level at $3.3409 during the session, while it also had its lowest trading level at $2.9835.
Ratios:
To gain a deeper understanding of IOVA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.31 and its Current Ratio is at 3.74. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $17.
On July 29, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $19 to $10.
On November 20, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $12.Goldman initiated its Buy rating on November 20, 2023, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when Maynard Ryan D sold 50,000 shares for $10.06 per share. The transaction valued at 503,000 led to the insider holds 7,500 shares of the business.
Maynard Ryan D bought 50,000 shares of IOVA for $503,104 on Nov 12 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 1009861120 and an Enterprise Value of 744343232. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.16 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 4.537 whereas that against EBITDA is -2.056.
Stock Price History:
The Beta on a monthly basis for IOVA is 1.06, which has changed by -0.7403035 over the last 52 weeks, in comparison to a change of 0.017286062 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $14.23, while it has fallen to a 52-week low of $2.70. The 50-Day Moving Average of the stock is -23.90%, while the 200-Day Moving Average is calculated to be -59.94%.
Shares Statistics:
It appears that IOVA traded 9.69M shares on average per day over the past three months and 10638670 shares per day over the past ten days. A total of 305.25M shares are outstanding, with a floating share count of 265.54M. Insiders hold about 19.01% of the company’s shares, while institutions hold 64.90% stake in the company. Shares short for IOVA as of 1743379200 were 75186511 with a Short Ratio of 7.76, compared to 1740700800 on 59585491. Therefore, it implies a Short% of Shares Outstanding of 75186511 and a Short% of Float of 25.16.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
